1222. Risk Factors and Outcomes for Daptomycin Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

BACKGROUND: Daptomycin (dap) has been approved and successfully used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. However, reports of daptomycin nonsusceptible (DNS) MRSA strains have emerged over the recent years. This study describes the clinical characterist...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadid, Hind, Rizvi, Hira, Misikir, Helina, Baratz, Nathalie, Bardossy, Ana Cecilia, Sundaram, Ayesha, Haddad, Lillian, Perri, Mary Beth, Zervos, Marcus, Herc, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253196/
http://dx.doi.org/10.1093/ofid/ofy210.1055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253196/
http://dx.doi.org/10.1093/ofid/ofy210.1055

Ejemplares similares